|
1
|
Sun P, Wu Q, Ruan G, Zheng X, Song Y, Zhun
J, Wu L and Gotlieb WH: Expression patterns of maspin and mutant
p53 are associated with the development of gestational
trophoblastic neoplasia. Oncol Lett. 12:3135–3142. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Savage P, Williams J, Wong SL, Short D,
Casalboni S, Catalano K and Seckl M: The demographics of molar
pregnancies in England and Wales from 2000–2009. J Reprod Med.
55:341–345. 2010.PubMed/NCBI
|
|
3
|
Begum SA, Bhuiyan ZR, Akther R, Afroz R,
Chowdhury A and Keya KA: A review on gestational trophoblastic
disease. Bangladesh Med J. 44:2015.
|
|
4
|
Gestational Trophoblastic Disease
Treatment (PDQ®). Health Professional Version. In: PDQ
Cancer Information Summaries [Internet]. National Cancer Institute
(US). (Bethesda, MD). 2002.
|
|
5
|
Horowitz NS, Goldstein DP and Berkowitz
RS: Placental site trophoblastic tumors and epithelioid
trophoblastic tumors: Biology, natural history, and treatment
modalities. Gynecol Oncol. 144:208–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee YJ, Park JY, Kim DY, Suh DS, Kim JH,
Kim YM, Kim YT and Nam JH: Comparing and evaluating the efficacy of
methotrexate and actinomycin D as first-line single chemotherapy
agents in low risk gestational trophoblastic disease. J Gynecol
Oncol. 28:e82017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
May T, Goldstein DP and Berkowitz RS:
Current chemotherapeutic management of patients with gestational
trophoblastic neoplasia. Chemother Res Pract.
2011:8062562011.PubMed/NCBI
|
|
8
|
Guo J, Zhong C, Liu Q, Xu J, Zheng Y, Xu
S, Gao Y, Guo Y, Wang Y, Luo Q, et al: Intracranial choriocarcinoma
occurrence in males: Two cases and a review of the literature.
Oncol Lett. 6:1329–1332. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tian Q, Xue Y, Zheng W, Sun R, Ji W, Wang
X and An R: Overexpression of hypoxia-inducible factor 1α induces
migration and invasion through Notch signaling. Int J Oncol.
47:728–738. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seckl MJ, Sebire NJ and Berkowitz RS:
Gestational trophoblastic disease. Lancet. 376:717–729. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lurain JR: Gestational trophoblastic
disease I: Epidemiology, pathology, clinical presentation and
diagnosis of gestational trophoblastic disease, and management of
hydatidiform mole. Am J Obstet Gynecol. 203:531–539. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lima LL, Parente RC and Maestá I: Amim
Junior J, de Rezende Filho JF, Montenegro CA and Braga A: Clinical
and radiological correlations in patients with gestational
trophoblastic disease. Radiol Bras. 49:241–250. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Soper JT: Gestational trophoblastic
disease. Obstet Gynecol. 108:176–187. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ghaemmaghami F, Behtash N, Soleimani K and
Hanjani P: Management of patients with metastatic gestational
trophoblastic tumor. Gynecol Oncol. 94:187–190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
FIGO Committee on Gynecologic Oncology:
Current FIGO staging for cancer of the vagina, fallopian tube,
ovary, and gestational trophoblastic neoplasia. Int J Gynaecol
Obstet. 105:3–4. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen Y, Qian H, Wang H, Zhang X, Fu M,
Liang X, Ma Y, Zhan Q, Lin C and Xiang Y: Ad-PUMA sensitizes
drug-resistant choriocarcinoma cells to chemotherapeutic agents.
Gynecol Oncol. 107:505–512. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suksai M, Suwanrath C, Kor-Anantakul O,
Geater A, Hanprasertpong T, Atjimakul T and Pichatechaiyoot A:
Complete hydatidiform mole with co-existing fetus: Predictors of
live birth. Eur J Obstet Gynecol Reprod Biol. 212:1–8. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schwentner L, Schmitt W, Bartusek G,
Kreienberg R and Herr D: Cervical hydatidiform mole pregnancy after
missed abortion presenting with severe vaginal bleeding: Case
report and review of the literature. Eur J Obstet Gynecol Reprod
Biol. 156:9–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tse KY and Ngan HY: Gestational
trophoblastic disease. Best Pract Res Clin Obstet Gynaecol.
26:357–370. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McDonald TW and Ruffolo EH: Modern
management of gestational trophoblastic disease. Obstet Gynecol
Surv. 38:67–83. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ozalp SS, Telli E, Oge T, Tulunay G, Boran
N, Turan T, Yenen M, Kurdoglu Z, Ozler A, Yuce K, et al:
Multicenter analysis of gestational trophoblastic neoplasia in
Turkey. Asian Pac J Cancer Prev. 15:3625–3628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Akyol A, Şimşek M and Üçer Ö: Giant
invasive mole presenting as a cause of abdominopelvic mass in a
perimenopausal woman: An unusual presentation of a rare pathology.
Obstet Gynecol Sci. 59:548–553. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garner EI, Goldstein DP, Feltmate CM and
Berkowitz RS: Gestational trophoblastic disease. Clin Obstet
Gynecol. 50:112–122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ibi T, Hirai K, Bessho R, Kawamoto M,
Koizumi K and Shimizu K: Choriocarcinoma of the lung: Report of a
case. Gen Thorac Cardiovasc Surg. 60:377–380. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Berkowitz RS and Goldstein DP: Current
management of gestational trophoblastic diseases. Gynecol Oncol.
112:654–662. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Monchek R and Wiedaseck S: Gestational
trophoblastic disease: An overview. J Midwifery Womens Health.
57:255–259. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shih IM and Kurman RJ: The pathology of
intermediate trophoblastic tumors and tumor-like lesions. Int J
Gynecol Pathol. 20:31–47. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Scully RE and Young RH: Trophoblastic
pseudotumor: A reappraisal. Am J Surg Pathol. 5:75–76. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Behnamfar F, Rouholamin S and Esteki M:
Presentation of Placental Site Trophoblastic Tumor with Amenorrhea.
Adv Biomed Res. 6:292017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eckstein RP, Paradinas FJ and Bagshawe KD:
Placental site trophoblastic tumour (trophoblastic pseudotumour): A
study of four cases requiring hysterectomy including one fatal
case. Histopathology. 6:211–226. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Newlands ES, Mulholland PJ, Holden L,
Seckl MJ and Rustin GJ: Etoposide and cisplatin/etoposide,
methotrexate, and actinomycin D (EMA) chemotherapy for patients
with high-risk gestational trophoblastic tumors refractory to
EMA/cyclophosphamide and vincristine chemotherapy and patients
presenting with metastatic placental site trophoblastic tumors. J
Clin Oncol. 18:854–859. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park JW and Bae JW: Epithelioid
Trophoblastic Tumor in a Postmenopausal Woman: A Case Report. J
Menopausal Med. 22:50–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rodríguez-Trujillo A, Martínez-Serrano MJ,
Saco A and Torné A: Two cases of epithelioid trophoblastic tumors
in postmenopausal women. Menopause. 24:1304–1308. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Davis MR, Howitt BE, Quade BJ, Crum CP,
Horowitz NS, Goldstein DP and Berkowitz RS: Epithelioid
trophoblastic tumor: A single institution case series at the New
England Trophoblastic Disease Center. Gynecol Oncol. 137:456–461.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim JH, Lee SK, Hwang SH, Kim JS, Yoon G,
Lee YY, Kim TJ, Choi CH, Kim BG, Bae DS, et al: Extrauterine
epithelioid trophoblastic tumor in hysterectomized woman. Obstet
Gynecol Sci. 60:124–128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abrão RA, de Andrade JM, Tiezzi DG, Marana
HR, Candido dos Reis FJ and Clagnan WS: Treatment for low-risk
gestational trophoblastic disease: Comparison of single-agent
methotrexate, dactinomycin and combination regimens. Gynecol Oncol.
108:149–153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lima LLA, Padron L, Câmara R, Sun SY,
Rezende J and Braga A: The role of surgery in the management of
women with gestational trophoblastic disease. Rev Col Bras Cir.
44:94–101. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Eoh KJ, Chung YS, Yim GW, Nam EJ, Kim S,
Kim SW and Kim YT: Role of surgical therapy in the management of
gestational trophoblastic neoplasia. Obstet Gynecol Sci.
58:277–283. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Berkowitz RS and Goldstein DP: Clinical
practice. Molar pregnancy. N Engl J Med. 360:1639–1645. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hurteau JA: Gestational trophoblastic
disease: Management of hydatidiform mole. Clin Obstet Gynecol.
46:557–569. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gerulath AH, Ehlen TG, Bessette P,
Jolicoeur L and Savoie R;: Society of Obstetricians and
Gynaecologists of CanadaGynaecologic Oncologists of Canada; Society
of Canadian Colposcopists: Gestational trophoblastic disease. J
Obstet Gynaecol Can. 24:434–446. 2002.(In English; French).
PubMed/NCBI
|
|
42
|
Sebire NJ and Seckl MJ: Gestational
trophoblastic disease: Current management of hydatidiform mole.
BMJ. 337:a11932008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kang WD, Choi HS and Kim SM: Weekly
methotrexate (50mg/m(2)) without dose escalation as a primary
regimen for low-risk gestational trophoblastic neoplasia. Gynecol
Oncol. 117:477–480. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
De Vos M, Leunen M, Fontaine C and De
Sutter P: Successful Primary Treatment of a Hydatidiform Mole with
Methotrexate and EMA/CO. Case Rep Med. 2009:4541612009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shanbhogue AK, Lalwani N and Menias CO:
Gestational trophoblastic disease. Radiol Clin North Am.
51:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wenzel L, Berkowitz RS, Newlands E,
Hancock B, Goldstein DP, Seckl MJ, Habbal R, Bernstein M, Kluhsman
B, Kulchak-Rahm A, et al: Quality of life after gestational
trophoblastic disease. J Reprod Med. 47:387–394. 2002.PubMed/NCBI
|
|
47
|
Lurain JR: Gestational trophoblastic
disease II: Classification and management of gestational
trophoblastic neoplasia. Am J Obstet Gynecol. 204:11–18. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Karjoo Z, Chen X and Hatefi A: Progress
and problems with the use of suicide genes for targeted cancer
therapy. Adv Drug Deliv Rev. 99(Pt A): 113–128. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zawilska JB, Wojcieszak J and Olejniczak
AB: Prodrugs: a challenge for the drug development. Pharmacol Rep.
65:1–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Schellmann N, Deckert PM, Bachran D, Fuchs
H and Bachran C: Targeted enzyme prodrug therapies. Mini Rev Med
Chem. 10:887–904. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Springer CJ, Bagshawe KD, Sharma SK,
Searle F, Boden JA, Antoniw P, Burke PJ, Rogers GT, Sherwood RF and
Melton RG: Ablation of human choriocarcinoma xenografts in nude
mice by antibody-directed enzyme prodrug therapy (ADEPT) with three
novel compounds. Eur J Cancer. 27:1361–1366. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bagshawe KD, Springer CJ, Searle F,
Antoniw P, Sharma SK, Melton RG and Sherwood RF: A cytotoxic agent
can be generated selectively at cancer sites. Br J Cancer.
58:700–703. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang J, Kale V and Chen M: Gene-directed
enzyme prodrug therapy. AAPS J. 17:102–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Weyel D, Sedlacek HH, Müller R and
Brüsselbach S: Secreted human beta-glucuronidase: A novel tool for
gene-directed enzyme prodrug therapy. Gene Ther. 7:224–231. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Alenzi FQ, Lotfy M, Tamimi WG and Wyse RK:
Review: Stem cells and gene therapy. Lab Hematol. 16:53–73. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Müller FJ, Snyder EY and Loring JF: Gene
therapy: Can neural stem cells deliver? Nat Rev Neurosci. 7:75–84.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Benedetti S, Pirola B, Pollo B, Magrassi
L, Bruzzone MG, Rigamonti D, Galli R, Selleri S, Di Meco F, De
Fraja C, et al: Gene therapy of experimental brain tumors using
neural progenitor cells. Nat Med. 6:447–450. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Aboody KS, Brown A, Rainov NG, Bower KA,
Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, et al:
Neural stem cells display extensive tropism for pathology in adult
brain: Evidence from intracranial gliomas. Proc Natl Acad Sci USA.
97:12846–12851. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ahmed AU, Alexiades NG and Lesniak MS: The
use of neural stem cells in cancer gene therapy: Predicting the
path to the clinic. Curr Opin Mol Ther. 12:546–552. 2010.PubMed/NCBI
|
|
60
|
Consiglio A, Gritti A, Dolcetta D,
Follenzi A, Bordignon C, Gage FH, Vescovi AL and Naldini L: Robust
in vivo gene transfer into adult mammalian neural stem cells by
lentiviral vectors. Proc Natl Acad Sci USA. 101:14835–14840. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Heo JR, Kim NH, Cho J and Choi KC: Current
treatments for advanced melanoma and introduction of a promising
novel gene therapy for melanoma (Review). Oncol Rep. 36:1779–1786.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhao D, Najbauer J, Garcia E, Metz MZ,
Gutova M, Glackin CA, Kim SU and Aboody KS: Neural stem cell
tropism to glioma: Critical role of tumor hypoxia. Mol Cancer Res.
6:1819–1829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yi BR, Hwang KA, Aboody KS, Jeung EB, Kim
SU and Choi KC: Selective antitumor effect of neural stem cells
expressing cytosine deaminase and interferon-beta against ductal
breast cancer cells in cellular and xenograft models. Stem Cell Res
(Amst). 12:36–48. 2014. View Article : Google Scholar
|
|
64
|
Yi BR, Kim SU and Choi KC: Co-treatment
with therapeutic neural stem cells expressing carboxyl esterase and
CPT-11 inhibit growth of primary and metastatic lung cancers in
mice. Oncotarget. 5:12835–12848. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Magge SN, Malik SZ, Royo NC, Chen HI, Yu
L, Snyder EY, O'Rourke DM and Watson DJ: Role of monocyte
chemoattractant protein-1 (MCP-1/CCL2) in migration of neural
progenitor cells toward glial tumors. J Neurosci Res. 87:1547–1555.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Bonini C, Bondanza A, Perna SK, Kaneko S,
Traversari C, Ciceri F and Bordignon C: The suicide gene therapy
challenge: how to improve a successful gene therapy approach. Mol
Ther. 15:1248–1252. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Joo KM, Park IH, Shin JY, Jin J, Kang BG,
Kim MH, Lee SJ, Jo MY, Kim SU and Nam DH: Human neural stem cells
can target and deliver therapeutic genes to breast cancer brain
metastases. Mol Ther. 17:570–575. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Green LK, Storey MA, Williams EM,
Patterson AV, Smaill JB, Copp JN and Ackerley DF: The Flavin
Reductase MsuE Is a Novel Nitroreductase that Can Efficiently
Activate Two Promising Next-Generation Prodrugs for Gene-Directed
Enzyme Prodrug Therapy. Cancers (Basel). 5:985–997. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Park GT, Kim SU and Choi KC:
Anti-proliferative Effect of Engineered Neural Stem Cells
Expressing Cytosine Deaminase and Interferon-beta against Lymph
Node-Derived Metastatic Colorectal Adenocarcinoma in Cellular and
Xenograft Mouse Models. Cancer Res Treat. 49:79–91. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Xie Y, Gilbert JD, Kim JH and Freytag SO:
Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine
kinase/ganciclovir suicide gene therapies concomitant with p53 gene
therapy. Clin Cancer Res. 5:4224–4232. 1999.PubMed/NCBI
|
|
71
|
Mahan SD, Ireton GC, Knoeber C, Stoddard
BL and Black ME: Random mutagenesis and selection of Escherichia
coli cytosine deaminase for cancer gene therapy. Protein Eng
Des Sel. 17:625–633. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Vermes A, Guchelaar HJ and Dankert J:
Flucytosine: A review of its pharmacology, clinical indications,
pharmacokinetics, toxicity and drug interactions. J Antimicrob
Chemother. 46:171–179. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ardiani A, Johnson AJ, Ruan H,
Sanchez-Bonilla M, Serve K and Black ME: Enzymes to die for:
Exploiting nucleotide metabolizing enzymes for cancer gene therapy.
Curr Gene Ther. 12:77–91. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kim DJ, Yi BR, Lee HR, Kim SU and Choi KC:
Pancreatic tumor mass in a xenograft mouse model is decreased by
treatment with therapeutic stem cells following introduction of
therapeutic genes. Oncol Rep. 30:1129–1136. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Yi BR, Park MA, Lee HR, Kang NH, Choi KJ,
Kim SU and Choi KC: Suppression of the growth of human colorectal
cancer cells by therapeutic stem cells expressing cytosine
deaminase and interferon-β via their tumor-tropic effect in
cellular and xenograft mouse models. Mol Oncol. 7:543–554. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Yi BR, Kim SU and Choi KC: Additional
effects of engineered stem cells expressing a therapeutic gene and
interferon-β in a xenograft mouse model of endometrial cancer. Int
J Oncol. 47:171–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Panelli MC and Marincola FM: Immunotherapy
update: from interleukin-2 to antigen-specific therapy. ASCO
educational book. Perry MC: American Society of Clinical Oncology.
467–473. 1998.
|
|
78
|
Kim GS, Heo JR, Kim SU and Choi KC:
Cancer-Specific Inhibitory Effects of Genetically Engineered Stem
Cells Expressing Cytosine Deaminase and Interferon-β Against
Choriocarcinoma in Xenografted Metastatic Mouse Models. Transl
Oncol. 11:74–85. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zwaka TP: Use of Genetically Modified Stem
Cells in Experimental Gene Therapies. National Institutes of Health
(US). (Bethesda, MD). 2006.
|
|
80
|
Ehtesham M, Kabos P, Kabosova A, Neuman T,
Black KL and Yu JS: The use of interleukin 12-secreting neural stem
cells for the treatment of intracranial glioma. Cancer Res.
62:5657–5663. 2002.PubMed/NCBI
|
|
81
|
Yuan X, Hu J, Belladonna ML, Black KL and
Yu JS: Interleukin-23-expressing bone marrow-derived neural
stem-like cells exhibit antitumor activity against intracranial
glioma. CancerRes. 66:2630–2638. 2006.
|
